keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation of chemotherapy treatment

keyword
https://www.readbyqxmd.com/read/27902541/central-serous-chorioretinopathylike-mimicking-multifocal-vitelliform-macular-dystrophy-an-ocular-side-effect-of-mitogen-extracellular-signal-regulated-kinase-inhibitors
#1
Chiara Giuffrè, Elisabetta Miserocchi, Giulio Modorati, Adriano Carnevali, Alessandro Marchese, Lea Querques, Giuseppe Querques, Francesco Bandello
PURPOSE: To describe a case of multiple detachments of the neurosensory retina mimicking multifocal vitelliform macular dystrophy after chemotherapy with mitogen/extracellular signal-regulated kinase inhibitor for metastatic ovarian cancer. METHODS: Case report. RESULTS: A 38-year-old woman presented to our clinic for eye examination before the initiation of chemotherapy with trametinib. One month after starting treatment, the patient complained of vision loss and metamorphopsia in both eyes...
November 29, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27897026/-acute-myocardial-infarction-complicated-pregnancy-of-patient-after-kindey-transplantation-and-knee-osteosarcoma
#2
K Lehnertová, K Huml, R Pilka
OBJECTIVE: Case report describes a patient with acute ST elevation myocardial infarction with Q wave in 26 weeks gestation. DESIGN: Case report. SETTING: Department of Obstetrics and Gynecology, University Hospital, Palacky University, Olomouc. CASE REPORT: Medical history is complicated with a cadaveric transplantation of kindey, osteosarcoma of the left knee with a joint extraction and chemotherapy, serious hypothyreosis after spontaneous discontinuation of medication and missing fetal nasal bone at the ultrasound examination...
2016: Ceská Gynekologie
https://www.readbyqxmd.com/read/27895740/letrozole-as-second-line-hormonal-treatment-for-recurrent-low-grade-endometrial-stromal-sarcoma-a-case-report-and-review-of-the-literature
#3
Kohei Nakamura, Kentaro Nakayama, Masako Ishikawa, Noriyoshi Ishikawa, Hiroshi Katagiri, Atsuko Katagiri, Tomoka Ishibashi, Emi Sato, Kohji Iida, Razia Sultana, Satoru Kyo
Low-grade endometrial stromal sarcoma (LGESS) is a rare malignancy. The tumor is reportedly responsive to hormonal therapy, most commonly with medroxyprogesterone acetate (MPA), but the effectiveness of aromatase inhibitors for recurrent LGESS remains unclear. The present study reports a case of stage IC LGESS presenting with abnormal uterine bleeding, and also provides a review of the literature. Following a total abdominal hysterectomy and bilateral salpingo-oophorectomy, MPA therapy was initiated; treatment was successful, but discontinued 19 months later due to disruptive side effects...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27890446/efficacy-of-therapies-after-galeterone-in-patients-with-castration-resistant-prostate-cancer
#4
Rana R McKay, Lillian Werner, Matthew Fiorillo, Jennifer Roberts, Elisabeth I Heath, Glenn J Bubley, Robert Bruce Montgomery, Mary-Ellen Taplin
BACKGROUND: Galeterone is a multi-targeted agent with activity as a CYP17 inhibitor, androgen receptor antagonist, and also causes androgen receptor degradation. It has shown meaningful anti-tumor activity with a well-tolerated safety profile in patients with castration-resistant prostate cancer (CRPC) in phase I and II studies; however, the efficacy of currently approved CRPC therapies after treatment with galeterone is unknown. In this study, we evaluate prostate specific antigen (PSA) response of non-protocol therapies following galeterone in a subset of patients treated on the Androgen Receptor Modulation Optimized for Response (ARMOR) 2 study...
October 27, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27886859/tolerability-and-efficacy-of-afatinib-at-a-low-starting-dosage-in-10-elderly-or-low-performance-status-patients-with-advanced-refractory-non-small-cell-lung-cancer
#5
Kosuke Kashiwabara, Hiroshi Semba, Shinji Fujii, Shinsuke Tsumura
BACKGROUND: Whether a full dosage of afatinib is tolerable and effective for elderly or low performance status (PS) patients with advanced refractory non-small-cell lung cancer (NSCLC) is unclear. METHODS: We retrospectively evaluated the tolerability and efficacy of afatinib in 10 patients (the majority elderly) with a low PS score (2 or 3), who had advanced refractory adenocarcinoma and were carrying active epidermal growth factor receptor mutations. Afatinib was administered at a starting dosage of 20 or 30mg/day, followed by 10mg increases in dose up to a maximum dosage of 40mg/day...
November 2016: Respiratory Investigation
https://www.readbyqxmd.com/read/27884722/the-impact-of-age-on-quality-of-life-in-breast-cancer-patients-receiving-adjuvant-chemotherapy-a-comparative-analysis-from-the-prospective-multicenter-randomized-adebar-trial
#6
Elena Leinert, Susanne Singer, Wolfgang Janni, Nadia Harbeck, Tobias Weissenbacher, Brigitte Rack, Doris Augustin, Arthur Wischnik, Marion Kiechle, Johannes Ettl, Visnja Fink, Lukas Schwentner, Martin Eichler
BACKGROUND: Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged < 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial...
October 19, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27872670/meaning-making-process-related-to-temporality-during-breast-cancer-traumatic-experience-the-clinical-use-of-narrative-to-promote-a-new-continuity-of-life
#7
Maria Luisa Martino, Maria Francesca Freda
Previous research has agreed that meaning-making is a key element in the promotion of patients' well-being during and after a traumatic event such as cancer. In this paper, we focus on an underestimated key element related to the crisis/rupture of this meaning-making process with respect to the time perspective. We consider 40 narratives of breast cancer patients at different times of treatment, undergoing chemotherapy and biological therapy. We collected data through writing technique. We performed an interpretative thematic analysis of the data and highlighted specific ways to signify time during the different treatment phases...
November 2016: Europe's journal of psychology
https://www.readbyqxmd.com/read/27852186/supportive-care-of-women-with-breast-cancer-key-concerns-and-practical-solutions
#8
Nicholas Zdenkowski, Stephanie Tesson, Janine Lombard, Melanie Lovell, Sandra Hayes, Prudence A Francis, Haryana M Dhillon, Frances M Boyle
Patients diagnosed with breast cancer may have supportive care needs for many years after diagnosis. High quality multidisciplinary care can help address these needs and reduce the physical and psychological effects of breast cancer and its treatment. Ovarian suppression and extended endocrine therapy benefits are associated with vasomotor, musculoskeletal, sexual and bone density-related side effects. Aromatase inhibitor musculoskeletal syndrome is a common reason for treatment discontinuation. Treatment strategies include education, exercise, simple analgesia and a change to tamoxifen or another aromatase inhibitor...
November 21, 2016: Medical Journal of Australia
https://www.readbyqxmd.com/read/27847222/use-of-maintenance-endocrine-therapy-after-chemotherapy-in-metastatic-breast-cancer
#9
REVIEW
S Sutherland, D Miles, A Makris
BACKGROUND: For women with oestrogen receptor+ metastatic breast cancer (MBC), the options for systemic treatment include endocrine therapy (ET) and chemotherapy. For women whose disease is also HER2+, anti-HER2 therapies are also routinely used either with chemotherapy or less commonly with ET. Where chemotherapy is used as initial therapy, treatment is often discontinued due to cumulative toxicity in the absence of disease progression. In this setting, there is the option of introducing ET with the aim of prolonging response and delaying relapse...
November 12, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27833388/effects-of-an-oral-iron-chelator-deferasirox-on-advanced-hepatocellular-carcinoma
#10
Issei Saeki, Naoki Yamamoto, Takahiro Yamasaki, Taro Takami, Masaki Maeda, Koichi Fujisawa, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Koichi Uchida, Kenji Tani, Isao Sakaida
AIM: To evaluate the inhibitory effects of deferasirox (DFX) against hepatocellular carcinoma (HCC) through basic and clinical studies. METHODS: In the basic study, the effect of DFX was investigated in three hepatoma cell lines (HepG2, Hep3B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day...
October 28, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27826583/weight-gain-as-a-surrogate-marker-of-longer-survival-in-advanced-non-small-cell-lung-cancer-patients
#11
COMMENT
Erkan Topkan
Weight loss (WL), as a key step of the irreversible and fatal cancer-related anorexia cachexia syndrome is present to some degree in 80% of non-small cell lung cancer (NSCLC) patients upon diagnosis which has been clearly proved to negatively alter patients' performance status, quality of life (QOL), response to treatment, and prognosis. However, WL is not a problem encountered only upon diagnosis but is also commonly reported during the course of aggressive chemotherapy, radiotherapy (RT) and particularly the concurrent chemoradiotherapy (C-CRT) which may further diminish QOL measures and clinical outcomes...
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27809894/interstitial-pneumonia-in-a-patient-treated-with-tas-102-for-metastatic-colorectal-cancer-a-case-report
#12
Hideki Kamei, Nobuya Ishibashi, Masahiko Tanigawa, Keizo Yamaguchi, Masafumi Uchida, Yoshito Akagi
BACKGROUND: TAS-102, a new treatment option for patients with metastatic colorectal cancer that is refractory or intolerant to standard therapies, has been improving survival with acceptable tolerability and adverse events. Adverse hematological events associated with TAS-102 treatment were extensively profiled in the RECOURSE trial, but pulmonary toxicities associated with TAS-102 therapy are distinctly uncommon. In a recent early post-marketing phase vigilance on TAS-102 in Japan, seven cases of pulmonary disease were reported, but patient follow-up in this study was incomplete...
November 3, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27799506/personalized-treatment-for-a-patient-with-a-braf-v600e-mutation-using-dabrafenib-and-a-tumor-treatment-fields-device-in-a-high-grade-glioma-arising-from-ganglioglioma
#13
Silviya K Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A Elvin, Norma Palma, Jeffrey S Ross, Vincent A Miller, Philip J Stephens, George Snipes, Veena Rajaram, Siraj M Ali, Isaac Melguizo-Gavilanes
BACKGROUND: Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However, some patients will experience tumor recurrence and/or malignant progression. This article reports on the clinical history, molecular findings, and treatment response in a patient with BRAF V600-mutated high-grade glioma arising from ganglioglioma. METHODS: Hematoxylin-eosin staining and comprehensive genomic profiling via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27794123/bmi-lifestyle-factors-and-taxane-induced-neuropathy-in-breast-cancer-patients-the-pathways-study
#14
Heather Greenlee, Dawn L Hershman, Zaixing Shi, Marilyn L Kwan, Isaac J Ergas, Janise M Roh, Lawrence H Kushi
BACKGROUND: Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer. METHODS: Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25 kg/m(2); overweight: 25-29.9 kg/m(2); obese: ≥30 kg/m(2)), moderate-to-vigorous physical activity (MVPA) (low: <2...
February 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27784460/-effect-of-traditional-chinese-medicine-treatment-as-maintenance-therapy-on-regulating-the-serum-concentration-of-sctla-4-in-patients-with-advanced-non-small-cell-lung-cancer-and-its-relationship-with-prognosis
#15
Y Jiang, L B Wu, L P Shen, P Zhang, W J Jiang, J H Tian, L S Liu
Objective: To evaluate the effect of traditional Chinese medicine (TCM) treatment as maintenance therapy on regulating the serum concentration of soluble cytotoxic T lymphocyte associated antigen-4 (sCTLA-4) in patients with advanced non-small-cell lung cancer (NSCLC) and the relationship between sCTLA-4 and time to progression (TTP). Methods: This study was conducted as a prospective, randomized, controlled trial. 64 non-progressive patients who responded to initial therapy were randomized 1∶1 to the TCM arm (treated with cinobufacini injection, herbal decoction and Chinese acupoint application, n=32) or to the chemotherapy arm (n=32)...
October 23, 2016: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/27783280/optimal-primary-febrile-neutropenia-prophylaxis-for-patients-receiving-docetaxel-cyclophosphamide-chemotherapy-for-breast-cancer-a-systematic-review
#16
REVIEW
Ricardo Fernandes, Sasha Mazzarello, Carol Stober, Lisa Vandermeer, Shaan Dudani, Mohamed F K Ibrahim, Habeeb Majeed, Kirstin Perdrizet, Risa Shorr, Brian Hutton, Dean Fergusson, Mark Clemons
BACKGROUND: Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address this knowledge gap. METHODS: Embase, Ovid Medline, Pubmed, the Cochrane database of systematic reviews, and Cochrane register of controlled trials were searched from 1946 to April 2016 for studies evaluating primary prophylactic FN treatments in breast cancer patients receiving DC chemotherapy...
October 25, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27777772/urothelial-carcinoma-of-donor-origin-in-a-kidney-transplant-patient
#17
Rosa M Michel Ortega, Daynna J Wolff, Cynthia A Schandl, Harry A Drabkin
BACKGROUND: Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant state. Donor-derived malignancy is a rare reported complication. Herein, we review our patient history and discuss diagnostic strategies and the implications of immunosuppression for donor-derived malignancy. CASE PRESENTATION: This is a 69-year-old man with post-renal-transplant urothelial carcinoma determined to be of donor origin...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27771885/capecitabine-in-combination-with-docetaxel-in-first-line-in-her2-negative-metastatic-breast-cancer-an-observational-study
#18
Renáta Kószó, Dóra Sántha, László Büdi, József Erfán, Károly Győrfy, Zsolt Horváth, Judit Kocsis, László Landherr, Erika Hitre, Károly Máhr, Gábor Pajkos, Zsuzsanna Pápai, Zsuzsanna Kahán
Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs...
October 22, 2016: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/27767430/a-systematic-review-of-adverse-event-reporting-in-companion-animal-clinical-trials-evaluating-cancer-treatment
#19
Michelle A Giuffrida
OBJECTIVE To evaluate methods used to ascertain, define, and report adverse events (AEs) in companion animal clinical trials involving cancer treatment. DESIGN Systematic review. SAMPLE English-language articles describing prospective clinical trials involving dogs and cats with naturally occurring cancer published in peer-reviewed journals between 2008 and 2014. PROCEDURES Reports were identified via MEDLINE and CAB database searches combined with a hand-searching strategy. General article characteristics were abstracted and summarized...
November 1, 2016: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/27764781/a-phase-ii-open-label-multicenter-study-of-gefitinib-in-combination-with-irradiation-followed-by-chemotherapy-in-patients-with-inoperable-stage-iii-non-small-cell-lung-cancer
#20
Antonin Levy, Etienne Bardet, Benjamin Lacas, Jean-Pierre Pignon, Julien Adam, Ludovic Lacroix, Xavier Artignan, Pierre Verrelle, Cécile Le Péchoux
BACKGROUND: Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer. PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status...
October 18, 2016: Oncotarget
keyword
keyword
31212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"